Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Legislation topic
No spam. Unsubscribe anytime.
OMMA staff outlines dozens of 2025 bills that could change medical marijuana rules in Oklahoma
Summary
OMMA staff told the Executive Advisory Council that hundreds of bills were filed at the legislative deadline and highlighted a slate of measures that would affect patient limits, advertising, transport, research licensing and enforcement authority for non‑delta‑9 products.
At a meeting of the OMMA Executive Advisory Council, agency staff reviewed dozens of bills filed in the current legislative session that may affect medical marijuana regulation, patients and licensees in Oklahoma.
The review, presented by Ashley Kroll, OMMA director of government affairs, covered measures that would change purchase limits, advertising restrictions, licensing processes and agency authority over certain hemp‑derived products. Kroll said thousands of bills were filed the previous day and the agency is still reading and tracking language that could affect patients and businesses.
Why it matters: Several bills on the agency’s list would directly change how medical marijuana is bought, transported and advertised in the state, and some would alter licensing or reporting duties for the Oklahoma Medical Marijuana Authority (OMMA).
Key measures summarized by Kroll included:
- House Bill 1163 (reported as “House Bill 11 63”): amends unspecified language and would create a misdemeanor offense punishable by a fine up to $400 (bill text not detailed in the presentation). Kroll noted the agency is still reviewing language. (Bill text not specified.)
- House Bill 1750 (noted by staff as a house “shell” bill): currently contains no substantive language and may be used later as a vehicle for other policy proposals.
- Senate Bill 23 (Sen. Stanley): would prohibit smoking tobacco, marijuana and vapor product use in a motor vehicle in the presence of a minor.
- Senate Bill 39 (Sen. Daniels): would prohibit carrying or using firearms while under the influence of medical marijuana and would clarify how medical‑marijuana users qualify for a handgun license.
- Senate Bill 191 (Sen. Devers): would restrict certain advertising by medical‑marijuana businesses, including statements that suggest marijuana is harmless or a safer alternative; it would also place limits on discounts and coupons and restrict some types of advertising outside dispensaries.
- Senate Bill 205 (Sen. Jett): would authorize OMMA to issue research licenses to facilitate collection and analysis of patient data and outcomes.
- Senate Bill 320 (Sen. Burns): would place a weekly purchase limit on licensed medical‑marijuana patients of 2.5 ounces per week.
- Additional bills summarized would: change patient‑license identifiers (SB774), permit transport of products to patients by licensed transporters (SB534), limit business ownership by nonresidents (SB640), allow temporary warehouse storage for transporters with tracking (SB697), add warning labels about driving under the influence (SB518), expand membership of the impaired driving prevention advisory committee to include OMMA leadership and other agencies (SB634), and add physician education requirements for recommending physicians (SB1066). Staff presented bill summaries as reported by sponsors; many bill texts and cross‑references remain under review.
On rulemaking and public comment, Kroll said OMMA received 283 comments on proposed permanent rule changes. About 70% of those comments addressed prepackaging requirements; 16% addressed an update report that the agency will publish by Feb. 1. Kroll directed council members to oma.ok.gov/comment for the rule summary and to oma.ok.gov/rules for current rules.
OMMA’s role: Kroll and Director Berry emphasized that the agency does not advocate for or against legislation. OMMA can provide licensing and tax data to legislators, identify potential fiscal impacts and share information about other states’ approaches, but the agency will not take positions for or against bills. Council members were urged to contact legislators directly and to engage early in the committee phase of the session.
Council discussion: Council member Katie Nail and others told staff they were particularly concerned about purchase‑limit proposals, saying some patients with advanced illnesses rely on larger quantities or concentrated products. Kroll said staff will share council feedback with bill authors and continue to monitor bill language as it develops.
What’s next: Kroll said OMMA will continue to update its legislation tracking page and may add explicit legislative‑calendar dates to help stakeholders target committee deadlines.
